These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34166445)

  • 1. A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies.
    Jensen SG; Epistolio S; Madsen CL; Kyneb MH; Riva A; Paganotti A; Barizzi J; Petersen RK; Børgesen M; Molinari F; Boldorini R; Lorenzen J; Sørensen E; Christensen UB; Høgdall E; Frattini M
    PLoS One; 2021; 16(6):e0253687. PubMed ID: 34166445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 4. Ultrasensitive and quantitative detection of EGFR mutations in plasma samples from patients with non-small-cell lung cancer using a dual PNA clamping-mediated LNA-PNA PCR clamp.
    Zhang S; Chen Z; Huang C; Ding C; Li C; Chen J; Zhao J; Miao L
    Analyst; 2019 Feb; 144(5):1718-1724. PubMed ID: 30663747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers.
    Gilson P; Saurel C; Salleron J; Husson M; Demange J; Merlin JL; Harlé A
    Sci Rep; 2021 May; 11(1):10470. PubMed ID: 34006948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of epidermal growth factor receptor mutation status in plasma and tissue samples of patients with non-small cell lung cancer.
    Roh MS; Yoon NB; Lee S; Kang BH; Um SJ; Lee DH; Son C
    J Cancer Res Ther; 2020; 16(4):843-849. PubMed ID: 32930128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy.
    Soria-Comes T; Palomar-Abril V; Ureste MM; Guerola MT; Maiques ICM
    Pathol Oncol Res; 2020 Apr; 26(2):845-851. PubMed ID: 30847713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
    Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
    Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients.
    Zaini J; Syahruddin E; Yunus M; Andarini SL; Hudoyo A; Masykura N; Yasril R; Ridwanuloh A; Hidajat H; Nurwidya F; Suharsono S; Utomo ARH
    Cancer Rep (Hoboken); 2019 Aug; 2(4):e1159. PubMed ID: 32721094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
    Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC
    Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
    Krug AK; Enderle D; Karlovich C; Priewasser T; Bentink S; Spiel A; Brinkmann K; Emenegger J; Grimm DG; Castellanos-Rizaldos E; Goldman JW; Sequist LV; Soria JC; Camidge DR; Gadgeel SM; Wakelee HA; Raponi M; Noerholm M; Skog J
    Ann Oncol; 2018 Mar; 29(3):700-706. PubMed ID: 29216356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implementation of circulating tumour DNA testing for
    Spence T; Perera S; Weiss J; Grenier S; Ranich L; Shepherd F; Stockley TL
    J Clin Pathol; 2021 Feb; 74(2):91-97. PubMed ID: 32471890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electric Field-Induced Release and Measurement (EFIRM): Characterization and Technical Validation of a Novel Liquid Biopsy Platform in Plasma and Saliva.
    Tu M; Cheng J; Chen YL; Jea WC; Chen WL; Chen CJ; Ho CL; Huang WL; Lin CC; Su WC; Ye Q; Deignan J; Grody W; Li F; Chia D; Wei F; Liao W; Wong DTW; Strom CM
    J Mol Diagn; 2020 Aug; 22(8):1050-1062. PubMed ID: 32497715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.
    Dono M; De Luca G; Lastraioli S; Anselmi G; Dal Bello MG; Coco S; Vanni I; Grossi F; Vigani A; Genova C; Ferrarini M; Ravetti JL; Zupo S
    Mol Med; 2019 Apr; 25(1):15. PubMed ID: 31029076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial).
    Usui K; Yokoyama T; Naka G; Ishida H; Kishi K; Uemura K; Ohashi Y; Kunitoh H
    Jpn J Clin Oncol; 2019 Jun; 49(6):554-558. PubMed ID: 30809659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations.
    Poole JC; Wu SF; Lu TT; Vibat CRT; Pham A; Samuelsz E; Patel M; Chen J; Daher T; Singh VM; Arnold LJ
    PLoS One; 2019; 14(10):e0223112. PubMed ID: 31581267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.
    Arriola E; Paredes-Lario A; García-Gomez R; Diz-Tain P; Constenla M; García-Girón C; Márquez G; Reck M; López-Vivanco G
    Clin Transl Oncol; 2018 Oct; 20(10):1261-1267. PubMed ID: 29623586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of
    Bai H; Xia J; Zhao X; Gong Z; Zhang D; Xiong L
    J Clin Pathol; 2019 May; 72(5):379-385. PubMed ID: 30787028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Color Crystal Digital PCR
    Madic J; Jovelet C; Dehri I; Mallory AC
    Methods Mol Biol; 2021; 2279():127-144. PubMed ID: 33683690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.